These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37923771)

  • 1. Regulation of eDHFR-tagged proteins with trimethoprim PROTACs.
    Etersque JM; Lee IK; Sharma N; Xu K; Ruff A; Northrup JD; Sarkar S; Nguyen T; Lauman R; Burslem GM; Sellmyer MA
    Nat Commun; 2023 Nov; 14(1):7071. PubMed ID: 37923771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy.
    Lee IK; Sharma N; Noguera-Ortega E; Liousia M; Baroja ML; Etersque JM; Pham J; Sarkar S; Carreno BM; Linette GP; Puré E; Albelda SM; Sellmyer MA
    Mol Ther; 2023 Dec; 31(12):3564-3578. PubMed ID: 37919903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
    Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
    J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
    Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
    J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene.
    Sellmyer MA; Richman SA; Lohith K; Hou C; Weng CC; Mach RH; O'Connor RS; Milone MC; Farwell MD
    Mol Ther; 2020 Jan; 28(1):42-51. PubMed ID: 31668558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTACS: A technology with a gold rush-like atmosphere.
    Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
    Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
    Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
    Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target protein localization and its impact on PROTAC-mediated degradation.
    Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
    Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical Dimerization-Induced Protein Condensates on Telomeres.
    Zhao R; Chenoweth DM; Zhang H
    J Vis Exp; 2021 Apr; (170):. PubMed ID: 33900288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
    Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
    Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
    Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
    Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vivo covalent TMP-tag based on proximity-induced reactivity.
    Gallagher SS; Sable JE; Sheetz MP; Cornish VW
    ACS Chem Biol; 2009 Jul; 4(7):547-56. PubMed ID: 19492849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection.
    Zahid S; Ali Y; Rashid S
    J Biomol Struct Dyn; 2023; 41(23):14566-14581. PubMed ID: 36841549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.